Clinical Scorecard: Wegovy and Possible Vision Risk
At a Glance
| Category | Detail |
|---|---|
| Condition | |
| Key Mechanisms | Potential link between high-dose semaglutide and optic nerve ischaemia due to rapid weight loss and metabolic shifts, as suggested by observational data. |
| Target Population | |
| Care Setting |
Key Highlights
- Semaglutide associated with significant signal for ION, particularly with Wegovy formulation, with a reported risk nearly five times higher than Ozempic.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Regular eye examinations for patients on high-dose semaglutide, ideally every 6 months.
Risks
Patient & Prescribing Data
Individuals with type 2 diabetes and obesity prescribed GLP-1RAs.
Wegovy may pose a higher risk for ION compared to other formulations.
Clinical Best Practices
- Implement routine eye screenings for patients on high-dose semaglutide every 6 months.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
